Press Release
AB-Therapeutics Hires José Alfón as Director of Development
Alfón, previously at Palau Pharma, will head the Catalan company’s R&D
January 3, 2011
The Catalan biotechnology company AB-Therapeutics, that focuses on drug development, has just hired José Alfón as Director of Development. Alfón previously served as Drug Development Project Leader at Palau Pharma.
In bringing Alfón aboard, AB-Therapeutics has finished putting together a solid team of scientists with broad international experience. His mission will be to direct the company’s recently begun preclinical development program for an anti-cancer drug candidate through the clinical phase.
José Alfón, 43, earned a Bachelor of Pharmacy and an MS in Pharmaceutical Sciences from the Hebrew University of Jerusalem, and a PhD in Pharmaceutical Sciences from the University of Barcelona (UB). He has over ten years experience in identifying drug candidates and in developing drugs from the discovery stage to Phase II clinical trials. In addition to Palau Pharma, where has spent most of his career to date, he has also held various research positions at the Hebrew University of Jerusalem, the Spanish National Research Council (CSIC), and different hospitals in the UK and Israel.
ABOUT AB-THERAPEUTICS
AB-Therapeutics, SL is a drug discovery and development company headquartered in Barcelona, Catalonia, Spain, with planned US facilities in Boston. The company was cofounded in late 2009 by AB Biotics, SA, a company publicly traded at the Spanish alternative stock market (MAB), Carles Domenech (CEO) and Jordi Espadaler (VP Discovery Research).
AB-Therapeutics, SL develops safer human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. It has a molecule ready to start preclinical development in 4Q2010, with Phase I clinical trials (first in man) starting in late 2011 / early 2012. A second drug candidate will start preclinical development in 2Q2011.
Contact:
Media relations:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com
In bringing Alfón aboard, AB-Therapeutics has finished putting together a solid team of scientists with broad international experience. His mission will be to direct the company’s recently begun preclinical development program for an anti-cancer drug candidate through the clinical phase.
José Alfón, 43, earned a Bachelor of Pharmacy and an MS in Pharmaceutical Sciences from the Hebrew University of Jerusalem, and a PhD in Pharmaceutical Sciences from the University of Barcelona (UB). He has over ten years experience in identifying drug candidates and in developing drugs from the discovery stage to Phase II clinical trials. In addition to Palau Pharma, where has spent most of his career to date, he has also held various research positions at the Hebrew University of Jerusalem, the Spanish National Research Council (CSIC), and different hospitals in the UK and Israel.
ABOUT AB-THERAPEUTICS
AB-Therapeutics, SL is a drug discovery and development company headquartered in Barcelona, Catalonia, Spain, with planned US facilities in Boston. The company was cofounded in late 2009 by AB Biotics, SA, a company publicly traded at the Spanish alternative stock market (MAB), Carles Domenech (CEO) and Jordi Espadaler (VP Discovery Research).
AB-Therapeutics, SL develops safer human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. It has a molecule ready to start preclinical development in 4Q2010, with Phase I clinical trials (first in man) starting in late 2011 / early 2012. A second drug candidate will start preclinical development in 2Q2011.
Contact:
Media relations:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com
LATEST NEWS
28.12.2020
Press Release
The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info
16.12.2020
Press Release
The antitumoral drug ABTL0812 shows promising results against neuroblastoma + info
05.11.2020
Press Release
AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020
Press Release
AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020
Press Release
ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020
Press Release
AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020
Press Release
AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019
Press Release
AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019
Press Release
Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
